Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 6.5% – What’s Next?

Cel-Sci Corporation (NYSEAMERICAN:CVM)’s stock price was down 6.5% during trading on Friday . The stock traded as low as $5.44 and last traded at $5.48. Approximately 58,410 shares traded hands during mid-day trading, a decline of 11% from the average daily volume of 65,541 shares. The stock had previously closed at $5.86.

Cel-Sci Trading Down 6.5%

The business’s 50 day moving average price is $6.17 and its 200-day moving average price is $7.28. The company has a current ratio of 2.26, a quick ratio of 2.20 and a debt-to-equity ratio of 0.36. The company has a market cap of $46.09 million, a price-to-earnings ratio of -0.56 and a beta of 0.54.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CVM. US Bancorp DE bought a new position in Cel-Sci during the 3rd quarter worth $80,000. MAI Capital Management increased its position in Cel-Sci by 18.4% during the third quarter. MAI Capital Management now owns 76,861 shares of the company’s stock worth $707,000 after acquiring an additional 11,928 shares during the period. Bank of America Corp DE raised its stake in Cel-Sci by 2,188.2% in the 2nd quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock worth $94,000 after purchasing an additional 39,190 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Cel-Sci by 59.7% in the 3rd quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock worth $2,692,000 after purchasing an additional 109,352 shares in the last quarter. 12.08% of the stock is owned by institutional investors and hedge funds.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.